Combination Products

Drug–Drug Combination can improve efficacy, simplify treatment, overcome resistance, or address several disease pathways at once. From an FDA perspective, the central question remains whether each component makes a meaningful contribution and whether the combination offers an acceptable benefit–risk profile. • Fixed-dose combinations, co-packaged products, and multidrug regimens. • FDA expectations for evidence supporting each component’s contribution to effect. • Dose, schedule, and formulation optimization for the overall regimen. • Assessment of pharmacokinetic and pharmacodynamic interactions. • Management of overlapping or additive toxicities. • Trial designs that separate the value of the combination from its individual components. • Growing use in oncology, cardiometabolic disease, and long-acting treatment regimens. • Additional complexity when two previously unapproved agents are developed together.

Drug–Device Combination range from prefilled syringes and autoinjectors to inhalers, wearable infusion systems, implants, and connected delivery platforms. From an FDA perspective, the review pathway is generally determined by the product’s primary mode of action, with coordination across FDA centers when needed. • Early product classification and lead-center assignment. • Compatibility between the drug and device constituent parts. • Human-factors and usability validation for patient-operated devices. • Dose-delivery accuracy, device reliability, and performance testing. • Manufacturing controls across both drug and device quality systems. • Bridging strategies following device, formulation, or design changes. • Clear labeling, instructions for use, and training requirements. • Unique Device Identification considerations, where applicable.

Drug–Companion Diagnostic Combinations are central to precision medicine, particularly where a biomarker test is essential to identify patients likely to benefit or avoid serious risks. Traditionally, the therapeutic and companion diagnostic are developed in parallel and reviewed through separate but coordinated drug and device applications, ideally reaching the market together. • Next-generation sequencing panels and liquid biopsies • Broader diagnostic labeling across classes of therapies • Decentralized testing and complex algorithms to interpret biomarkers • Early coordination between drug and diagnostic partners • Access to representative clinical specimens • Analytical and clinical validation • Maintaining alignment between therapeutic and diagnostic labeling